Use of ICDs for primary prevention following acute MI
This article has no abstract so we have provided the first paragraph of the full text.
In MADIT II, defibrillator implantation after myocardial infarction (MI) reduced sudden cardiac death by 67% in patients with a left ventricular ejection fraction (LVEF) of 30% or less. The FDA consequently approved implantable cardioverter-defibrillator (ICD) use in patients meeting the entry criteria for this trial, but there is still some controversy over the cost-effectiveness of ICDs in this patient group, and over the LVEF cutoff used to determine whether a device should be implanted.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
